Tech Company Financing Transactions
Ruxton Pharmaceuticals Funding Round
Ruxton Pharmaceuticals closed a $8 million Series A financing round on 11/10/2008. Investors included New Enterprise Associates.
Transaction Overview
Company Name
Announced On
11/10/2008
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
New Enterprise Associates (James Barrett)
Proceeds Purpose
The new investment will be used to advance clinical development of ecopipap for treatment of serious central nervous system disorders.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
2330 W. Joppa Road 355
Lutherville, MD 21093
USA
Lutherville, MD 21093
USA
Phone
Website
Email Address
Overview
Ruxton Pharmaceuticals is an emerging pharmaceutical company that has been formed to discover, develop and market drugs for the treatment of neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Chipkin
Chief Scientific Officer
Rita Sattler
Founder
Jeffrey Rothstein
Browse more venture capital transactions:
Prev: 11/10/2008: IdeaPaint venture capital transaction
Next: 11/10/2008: Precision Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs